Rui Lisheng (romiplostim biosimilar) / Qilu Pharma - LARVOL DELTA

An exploratory study of ropustine N01 in the treatment of thrombocytopenia (ctit) caused by immune combined with chemotherapy / targeted therapy in advanced solid tumors (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University

New trial • Gastric Cancer • Hematological Disorders • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov) - P2/3 | N=63 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jul 2023 ➔ Feb 2024 | Trial primary completion date: May 2023 ➔ Feb 2024

Trial completion • Trial completion date • Trial primary completion date • Hematological Disorders • Thrombocytopenia

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (clinicaltrials.gov) - P2/3 | N=235 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P2/3 trial • Hematological Disorders • Oncology • Thrombocytopenia

Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial. (PubMed, J Transl Int Med) - P3 | "QL0911, a biosimilar to romiplostim (Nplate®), may be a novel treatment option for patients with ITP who have failed or relapsed from first-line treatment in China. Ongoing studies will provide further data on long-term efficacy and safety in such patient populations."

Clinical • Journal • P3 data • Hematological Disorders • Infectious Disease • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura

EFFICACY AND SAFETY OF QL0911 IN ADULT PATIENTS WITH CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III TRIAL (EHA 2023) - P3 | "QL0911 was well tolerated, and increased and maintained platelet counts in adults with ITP. QL0911, as a biosimilar of romiplostim (Nplate®), may become a novel treatment option for ITP patients with failure or relapse from first-line treatment in China. Ongoing studies will provide further data as to long-term efficacy and safety in such patient populations."

Clinical • P3 data • Hematological Disorders • Infectious Disease • Musculoskeletal Pain • Nephrology • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov) - P2/3 | N=50 | Completed | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P2/3 trial • Hematological Disorders • Solid Tumor • Thrombocytopenia